DBV Technologies
http://www.dbv-technologies.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DBV Technologies
Novartis’s Peanut Allergy Setback Perks Up Rivals
Opportunity could knock for the smaller but more specialized players in the peanut allergy space now that Novartis has halted trials of its investigational IgE inhibitor ligelizumab.
Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts
Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.
Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
- Transdermal
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- ADMET
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice